Navigation Links
Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Date:8/27/2007

GAITHERSBURG, Md. and YOKOHAMA, Japan, Aug. 27 /PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announced today the signing of an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical studies and commercialization of Medinet's cancer immunotherapy service in Japan. Under terms of the agreement, MaxCyte will provide the exclusive right to utilize its proprietary technology in the closed-system manufacturing of Medinet's immuno-cell therapy service in multiple cell processing centers across Japan based on optimized protocols developed under the MaxCyte-Medinet collaboration announced in August, 2006.

"In our efforts to innovate technologies with higher efficacy, we chose MaxCyte as our partner to develop a novel technology in Dendritic Cell (DC) processing. Today, we are exceedingly pleased to announce that our joint efforts have been successful," said Mr. Yoshiji Kimura, Medinet's Chief Executive Officer. "Immuno-cell therapy is a treatment in which immune cells are taken from a cancer patient, cultured and processed to enhance their activity, then re-administered to the patient. We believe this therapeutic technology shows great potential and that the novel technology developed by MaxCyte and Medinet will improve the expected efficacy of the DC Vaccine Therapy technology of Medinet. On the basis of our Agreement, we plan implementation of this innovative technology in our Contracted Medical Institutions, which practice cancer immuno-cell therapy, in Spring 2008 after experiments at our Cell Processing Center. By improving the clinical outcome of cancer patients, MaxCyte's technology is expected to greatly enhance our reputation as leading providers of immunotherapy within Japan," he added.

"Medinet's proven track record in the area of immunotherapy makes them an excellent partner for MaxCyte," said Douglas A. Doerfler, MaxCyte's president and CEO. "This licensing pa
'/>"/>

SOURCE MaxCyte, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software
7. Marquette targets illegal downloading
8. Though VC investing is down, reloading on new funds is rising
9. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
10. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
11. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Vaccine for Animals to be Produced in Changzhou Hi-Tech ... ... -- A project for,producing inactivated rabies animal vaccines was recently launched ... product developed by a team of leading overseas scientists. It is,reported ...
... (Nasdaq: CVTX ) today reported financial results for the ... March 31, 2008, the Company reported a net loss,of $31.9 ... loss of $34.1,million, or $0.57 per share, for the prior ... share, for the same quarter in 2007., For the ...
... Study in Science, DRESDEN, Germany, April ... of RAFT intervention therapeutics, announced today the,publication ... potential novel strategy,for therapeutic intervention in Alzheimer,s ... the cell membrane (RAFTS). The study conducted,by ...
Cached Biology Technology:Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 2Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 3CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... organisms that have different traits yet to study, and ... information from organisms rapidly evolving, the "forest" of evolution ... individual case and detail. A review paper published ... Marvalee Wake and Chelsea Specht, all currently National Science ...
... for clues to improved treatments for some people with schizophrenia ... third of 1 percent of patients. In ... Health, schizophrenia patients were 14 times more likely than controls ... The mutations were in the gene for VIPR2, the receptor ...
... ANAHEIM, Calif., Feb. 24, 2011 For a week ... Los Angeles Angels baseball, and other attractions becomes the world ... gather here for the 241st National Meeting & Exposition of ... members, ACS is the world,s largest scientific society, and the ...
Cached Biology News:Rare gene glitch may hold clues for schizophrenia -- NIH-funded study 2Rare gene glitch may hold clues for schizophrenia -- NIH-funded study 3American Chemical Society National Meeting & Exposition, March 27-31, Anaheim, Calif. 2
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: